D-IX
Methamphetamine-based drug used in Nazi Germany
D-IX is a methamphetamine-based experimental performance enhancer developed by Nazi Germany in 1944 for military application. The researcher who rediscovered this project, Wolf Kemper, said, "the aim was to use D-IX to redefine the limits of human endurance." One dose contained 5 mg oxycodone (brand name Eukodal, an analgesic opioid), 5 mg cocaine, and 3 mg methamphetamine (brand name Pervitin).
German doctors were enthusiastic about the results, and planned to supply all German troops with the pills, but the war ended before D-IX could be put into mass production, though it did see limited use among a handful of Neger and Biber pilots.
History
Due to increased Allied pressure on the German war effort, Nazi Germany had grown desperate for more soldiers, and one way to mitigate the massive losses was to increase the combative power of existing Wehrmacht soldiers. Though simpler drugs, such as Pervitin and Isophan, helped to keep soldiers stimulated, in March 1944, Vice Admiral Hellmuth Heye requested a drug that could also give users superhuman strength and a boosted sense of self-esteem.
Pharmacologist Gerhard Orzechowski, and a group of other researchers, were commissioned to develop the drug in Kiel, and by later that year, had developed a formula that contained, in each tablet, 5 mg of oxycodone, 5 mg of cocaine, and 3 mg of methamphetamine.
The public source identifies “D-IX” as methamphetamine-based drug used in Nazi Germany. This brief keeps that definition visible, then builds a research path around D-IX, Methamphetamine-based and drug.
Why this record matters
A short description can identify a subject without explaining its stakes. For “D-IX”, the useful work is to connect “methamphetamine-based drug used in Nazi Germany” to the records capable of establishing context and consequence.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Jul 30, 2026. The linked authority identifier is Q1151289. None of the 1 selected statements returned an explicit reference. The first chronological checks are 1944.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “D-IX”, its source revision and the description used here.
- Expand the search: follow D-IX primary sources, D-IX archive and D-IX research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “D-IX”?
- Which institution is responsible for the underlying evidence?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “D-IX” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.